LONSURF

Peak

trifluridine and tipiracil

NDAORALTABLET
Approved
Sep 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
5

Mechanism of Action

Nucleic Acid Synthesis Inhibitors

Pharmacologic Class:

Nucleoside Analog Antiviral

Clinical Trials (5)

NCT06614192Phase 3Recruiting

A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

Started Nov 2024
460 enrolled
Metastatic Colorectal Cancer
NCT04046887Phase 1Terminated

Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)

Started Sep 2019
NCT03974594Phase 1Completed

Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients

Started May 2019
NCT03762161Phase 2Unknown

A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer

Started Jan 2019
NCT02921737Phase 2Terminated

TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003)

Started Nov 2017

Loss of Exclusivity

LOE Date
Feb 3, 2037
133 months away
Patent Expiry
Feb 3, 2037
Exclusivity Expiry
Feb 22, 2026

Patent Records (5)

Patent #ExpiryTypeUse Code
RE46284
Sep 22, 2029
U-3656
10457666
Jun 17, 2034
SubstanceProduct
9527833
Jun 17, 2034
SubstanceProduct
9943537
Sep 5, 2034
U-3659
10456399
Feb 3, 2037
U-3657